Cargando…

Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma

IMPORTANCE: Defining early reliable surrogate end points for survival in patients with hepatocellular carcinoma (HCC) after conventional transarterial chemoembolization (cTACE) is of great value. OBJECTIVE: To evaluate the association between sustained response duration (SRD) and overall survival (O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yaojun, Zhang, Mengping, Chen, Minshan, Mei, Jie, Xu, Li, Guo, Rongping, Lin, Xiaojun, Li, Jiaping, Peng, Zhenwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324454/ https://www.ncbi.nlm.nih.gov/pubmed/30646226 http://dx.doi.org/10.1001/jamanetworkopen.2018.3213

Ejemplares similares

Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma
por: Liu, Furong, et al.
Publicado: (2019)

Predictive factors for the benefit of triple‐drug transarterial chemoembolization for patients with unresectable hepatocellular carcinoma
por: He, MinKe, et al.
Publicado: (2019)

Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization
por: ZHOU, DONGSHENG, et al.
Publicado: (2016)

Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma
por: Labeur, Tim A., et al.
Publicado: (2018)

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015)

Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres(®) Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis
por: Liang, Bin, et al.
Publicado: (2021)

Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
por: Baur, Johannes, et al.
Publicado: (2016)

Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma
por: English, Keara, et al.
Publicado: (2020)

Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma
por: Fukushima, Taito, et al.
Publicado: (2021)

Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
por: Adel, Hatem, et al.
Publicado: (2023)

Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma
por: Duan, Xuhua, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
por: Zhou, Qunfang, et al.
Publicado: (2020)

Liver resection versus transarterial chemoembolization for the treatment of intermediate‐stage hepatocellular carcinoma
por: Chen, Shuling, et al.
Publicado: (2019)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Survival and Metastasis for Recurrent Hepatocellular Carcinoma after Transarterial Chemoembolization
por: Fan, Wenzhe, et al.
Publicado: (2015)

Preoperative Versus Postoperative Transarterial Chemoembolization on Prognosis of Large Hepatocellular Carcinoma
por: Wang, Xiaohui, et al.
Publicado: (2021)

Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula
por: Cai, Liang, et al.
Publicado: (2022)

Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma
por: Kong, Jie-Yu, et al.
Publicado: (2018)

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials
por: Huang, YeXing, et al.
Publicado: (2022)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma
por: Ren, Yanqiao, et al.
Publicado: (2022)

Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma
por: Song, Jeong Eun, et al.
Publicado: (2017)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Weihua, et al.
Publicado: (2021)

Laparoscopic Hepatectomy versus Open Hepatectomy After Conversion Therapy Using Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy for Patients with Initially Unresectable Hepatocellular Carcinoma
por: Yang, Zhenyun, et al.
Publicado: (2023)

Ultraselective conventional transarterial chemoembolization: When and how?
por: Miyayama, Shiro
Publicado: (2019)

Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study
por: Wen, Ping, et al.
Publicado: (2019)

Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients
por: Lee, In Joon, et al.
Publicado: (2019)

Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
por: Long, Teng, et al.
Publicado: (2023)

Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)

Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma
por: Le, Yong, et al.
Publicado: (2019)

DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study
por: Song, Do Seon, et al.
Publicado: (2013)

Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
por: Zhong, Bin-Yan, et al.
Publicado: (2023)

Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
por: Wang, Hongyu, et al.
Publicado: (2020)

Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus
por: Chen, Junwei, et al.
Publicado: (2023)

Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: Impact of Embolic Density and Residual Tumor Perfusion on Tumor Recurrence and Survival
por: Ruff, Christer, et al.
Publicado: (2021)

Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy
por: Ye, Zhiqiu, et al.
Publicado: (2021)

Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization
por: Parikh, Neehar D., et al.
Publicado: (2018)

Outcome of conventional transarterial chemoembolization (cTACE) in the management of spontaneously ruptured hepatocellular carcinoma
por: Patidar, Yashwant, et al.
Publicado: (2019)

Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)
por: de Baere, Thierry, et al.
Publicado: (2022)

Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
por: Chen, Shuling, et al.
Publicado: (2018)

Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study
por: Ouyang, Tao, et al.
Publicado: (2021)

Multivariate Analysis of the Predictors of Survival for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Focusing on Superselective Chemoembolization
por: Ji, Suk Kyeong, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_4pi5buun345o480sksaqgn41js